Description
Added on the 04/02/2021 13:00:00 - Copyright : EFE Inglés
Mainz (Germany), 10 Nov (EFE/EPA) - (Camera: Ronald Wittek) The American pharmaceutical company Pfizer and the German company BioNTech announced Monday that their experimental vaccine against covid-19 shows an effectiveness of more than 90% in the participants without previous evidence of infection, more than required by the US regulators and even than expected by their directors.FOOTAGE OF BIONTECH'S HEADQUARTERS IN MAINZ, GERMANY
Five top anti-vaccine advocacy groups received PPP funding from the Trump administration. The news was broken by the Washington Post American distrust in the safety of COVID-19 vaccinations continues to pose a threat to public health. A Harvard professor of health communication told Insider that anti-vaccine groups are "likely to perpetuate the adverse impacts of the pandemic."
President-elect Joe Biden received a dose of the Pfizer and BioNTech coronavirus vaccine on Monday afternoon. The first shot in a series of two was administered at ChristianaCare Hospital in Newark, Delaware. Biden's vaccination came one week after the first doses of the vaccine were given to health care workers. Biden noted that the vaccine rollout was in the beginning stages and cautioned Americans about the long road ahead. According to CNN President-elect Biden cautioned Americans saying: "It's going to take time". Biden urged Americans in the meantime to listen to public health experts, wear masks and maintain social distance.
Joe and Jill Biden will get the COVID vaccine on Monday. This news comes from the incoming White House press secretary Jen Psaki. Psaki also revealed that VP-elect Kamala Harris and Doug Emhoff, will receive their vaccinations the week after the Bidens. The Pfizer vaccine requires two doses given to patients several weeks apart. Business Insider said the Pfizer has been found to be 94.5% effective. On December 18, VP Mike Pence, second lady Karen Pence, and Surgeon General Jerome Adams received the vaccine on-camera.
Berlin, Sep 26 (EFE / EPA) .- (Camera: Hayoung Jeon) The passive vaccine against SARS-CoV-2 that is being developed in Berlin will not be the universal remedy to control the pandemic, but it does have the clear aim of minimizing symptoms in infected persons and also contributing to explain the existence of such diverse clinical pictures for the same virus.FOOTAGE AND SOUNDBITES OF HARALD PRÜß, DZNE INVESTIGATION GROUP LEADER.Translation: "The basic approach aims for patients who have become ill to present a mild evolution or even a remission of symptoms. However, we assume that for someone who is already seriously ill, who for example is already in the intensive care unit, this effect of the antibodies would come too late, because we know from recent studies that at that point inflammatory messenger substances and other aspects play a role and not so much the virus itself. ""In turn, the interesting question arises as to (...) if perhaps it exists in a part of the neurological conditions that we see in patients -also the long-term effects of COVID and other conditions-, a relationship with these cross-reactive antibodies. ""It could happen that the virus mutates and is able to evade this effective protection of antibodies. Theoretically it can also happen with our passive vaccine. That is why we have selected antibodies that adhere to particularly stable regions of the virus, that is, where mutations appear more rarely. "
|
Support : Technical 
- Content 
- Editors 
